Dear Editor,The ongoing COVID-19 disease,caused by severe acute respiratory syndrome coronavirus 2(SARS-Co V-2),has led to over 112 million confirmed cases and 2.4 million deaths in more than 220 countries as of 25 February 2021(WHO 2021).Hospital-admitted patients show clinical features ...
SARS-CoV-2GIBBS' free energyCOVID-19 treatmentA global challenge is presented by the continuous surge in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), leading to the COVID-19 pandemic. A major concern arises as SARS-CoV-2 undergoes mutations, potentia...
The outbreak of 2019-novel coronavirus disease (COVID-19), caused by SARS-CoV-2, started in late 2019; in a short time, it has spread rapidly all over the world. Although some possible antiviral and anti-inflammatory medications are available, thousands of people are dying daily. Well-under...
SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants John P. Moore, PhD; Paul A. Offit, MD JAMA Medical News & Perspectives Experts Discuss COVID-19—Vaccine Doses, Virus Variants, and More JAMA Viewpoint SARS-CoV-2 Variants of Concern in the United States ...
An analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes collected from more than 7500 patients worldwide has identified
Remdesivir (RDV) exhibits potent antiviral activity against SARS-CoV-2 and is currently the only drug approved for the treatment of COVID-19. However, little is currently known about the potential for pre-existing resistance to RDV and the possibility of SARS-CoV-2 genetic diversification that ...
SARS-CoV-2 infections display tremendous interindividual variability, ranging from asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies directed against, type I interferons (IFNs) account for about 20% of critical COV
2expression by 37% (P = 2.7 × 10−8) and reduces the risk of SARS-CoV-2 infection by 40% (odds ratio = 0.60,P = 4.5 × 10−13), providing human genetic evidence that ACE2 expression levels influence COVID-19 risk. We also replicate the associations of ...
The SARS-CoV S protein/ACE2 interface has been elucidated at the atomic level, and the ACE2 was found to be a key factor of SARS-CoV transmission (Li et al., 2005b). The binding mode of SARS-CoV-2 receptor binding domain (RBD) to ACE2 is nearly identical to SARS-CoV (Lan et ...
SARS-CoV-2 Omicron Genetic diversity 1. Introduction Since the emergence of the coronavirus disease 2019 (COVID-19) was firstly reported in December 2019, the frequent emerging events of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have raised significant concerns [1]. To...